Mitochondrial dysfunction as a trigger of programmed axon death
Copyright © 2021 Elsevier Ltd. All rights reserved..
Mitochondrial failure has long been associated with programmed axon death (Wallerian degeneration, WD), a widespread and potentially preventable mechanism of axon degeneration. While early findings in axotomised axons indicated that mitochondria are involved during the execution steps of this pathway, recent studies suggest that in addition, mitochondrial dysfunction can initiate programmed axon death without physical injury. As mitochondrial dysfunction is associated with disorders involving early axon loss, including Parkinson's disease, peripheral neuropathies, and multiple sclerosis, the findings that programmed axon death is activated by mitochondrial impairment could indicate the involvement of druggable mechanisms whose disruption may protect axons in such diseases. Here, we review the latest developments linking mitochondrial dysfunction to programmed axon death and discuss their implications for injury and disease.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2022 |
|---|---|
| Erschienen: |
2022 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:45 |
|---|---|
| Enthalten in: |
Trends in neurosciences - 45(2022), 1 vom: 01. Jan., Seite 53-63 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Merlini, Elisa [VerfasserIn] |
|---|
| Links: |
|---|
| Anmerkungen: |
Date Completed 07.04.2022 Date Revised 12.05.2022 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1016/j.tins.2021.10.014 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM333897986 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM333897986 | ||
| 003 | DE-627 | ||
| 005 | 20231225222605.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2022 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.tins.2021.10.014 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1112.xml |
| 035 | |a (DE-627)NLM333897986 | ||
| 035 | |a (NLM)34852932 | ||
| 035 | |a (PII)S0166-2236(21)00214-9 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Merlini, Elisa |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Mitochondrial dysfunction as a trigger of programmed axon death |
| 264 | 1 | |c 2022 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 07.04.2022 | ||
| 500 | |a Date Revised 12.05.2022 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Copyright © 2021 Elsevier Ltd. All rights reserved. | ||
| 520 | |a Mitochondrial failure has long been associated with programmed axon death (Wallerian degeneration, WD), a widespread and potentially preventable mechanism of axon degeneration. While early findings in axotomised axons indicated that mitochondria are involved during the execution steps of this pathway, recent studies suggest that in addition, mitochondrial dysfunction can initiate programmed axon death without physical injury. As mitochondrial dysfunction is associated with disorders involving early axon loss, including Parkinson's disease, peripheral neuropathies, and multiple sclerosis, the findings that programmed axon death is activated by mitochondrial impairment could indicate the involvement of druggable mechanisms whose disruption may protect axons in such diseases. Here, we review the latest developments linking mitochondrial dysfunction to programmed axon death and discuss their implications for injury and disease | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Research Support, Non-U.S. Gov't | |
| 650 | 4 | |a Review | |
| 650 | 4 | |a Parkinson’s disease | |
| 650 | 4 | |a SARM1 | |
| 650 | 4 | |a Wallerian degeneration | |
| 650 | 4 | |a axon degeneration | |
| 650 | 4 | |a mitochondrial dysfunction | |
| 650 | 4 | |a programmed axon death | |
| 650 | 7 | |a Armadillo Domain Proteins |2 NLM | |
| 650 | 7 | |a Cytoskeletal Proteins |2 NLM | |
| 700 | 1 | |a Coleman, Michael P |e verfasserin |4 aut | |
| 700 | 1 | |a Loreto, Andrea |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Trends in neurosciences |d 1987 |g 45(2022), 1 vom: 01. Jan., Seite 53-63 |w (DE-627)NLM012599522 |x 1878-108X |7 nnns |
| 773 | 1 | 8 | |g volume:45 |g year:2022 |g number:1 |g day:01 |g month:01 |g pages:53-63 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1016/j.tins.2021.10.014 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 45 |j 2022 |e 1 |b 01 |c 01 |h 53-63 | ||